Biogen

BIIB

Market cap $21.2B

Overview Fund Activity

144.63 USD

-0.24

0.17%

At close Updated Sep 18, 12:16 PM EDT

1 day

-0.17%

5 days

-2.33%

1 month

6.42%

3 months

14.3%

6 months

1.08%

Year to date

-3.58%

1 year

-26.8%

5 years

-47.31%

10 years

-54.04%

About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Employees: 7,605

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

150% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 5 (+3) [Q2]

29% more repeat investments, than reductions

Existing positions increased: 336 | Existing positions reduced: 260

14% more call options, than puts

Call options by funds: $381M | Put options by funds: $333M

1.4% more ownership

Funds ownership: 86.75% [Q1] → 88.15% (+1.4%) [Q2]

4% less first-time investments, than exits

New positions opened: 94 | Existing positions closed: 98

2% less funds holding

Funds holding: 867 [Q1] → 850 (-17) [Q2]

7% less capital invested

Capital invested by funds: $17.4B [Q1] → $16.2B (-$1.14B) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$118

18% downside

Avg. target

$162

12% upside

High target

$219

51% upside

5 analyst ratings

2 positive

40%

3 neutral

60%

0 negative

0%

Piper Sandler David Amsellem	$118	Neutral Maintained	14 Aug 2025
Citigroup Geoff Meacham	$135	Neutral Maintained	1 Aug 2025
RBC Capital Brian Abrahams	$219	Outperform Maintained	1 Aug 2025
Morgan Stanley Matthew Harrison	$144	Equal-Weight Maintained	1 Aug 2025
HC Wainwright & Co. Andrew Fein	$194	Buy Maintained	1 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 17 articles about BIIB published over the past 30 days

Zacks Investment Research

Biogen Gets EU Nod for First Postpartum Depression Drug

BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.

Biogen Gets EU Nod for First Postpartum Depression Drug

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics. As part of an existing partnership with Alcyone Therapeutics, the companies are advancing ThecaFlex DRx™, an implantable subcutaneous port and catheter device being investigated for the intrathecal delivery of antisense oligonucleotides (ASOs). ThecaFlex DRx™ is designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines, which could ease both patient experience and accessibility for a broader population of people living with neurologic disorders.

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) to treat post-partum depression (PPD) in adults following childbirth. ZURZUVAE is a once-daily, oral, 14-day treatment which represents a novel therapeutic approach, offering the first and only treatment indicated for PPD in the E.U.

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Biogen Inc. (NASDAQ:BIIB ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:45 AM EDT Company Participants Christopher Viehbacher - President, CEO & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Good morning, everybody.

Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Global drugmakers rush to boost US presence as tariff threat looms

Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

Global drugmakers rush to boost US presence as tariff threat looms

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies –

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen that support the potential for zorevunersen to be the first disease-modifying medicine for Dravet syndrome. Findings were presented at the 36th International Epil.

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More

Dow Set to Open Down as Markets Reopen After Labor Day S&P 500 and Nasdaq futures are also falling in premarket trading.

These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More

Zacks Investment Research

Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi

BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.

Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi

See News Rankings

Charts implemented using Lightweight Charts™